Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · IEX Real-Time Price · USD
13.34
-0.63 (-4.51%)
At close: Apr 19, 2024, 4:00 PM
13.36
+0.02 (0.15%)
After-hours: Apr 19, 2024, 6:59 PM EDT
Cabaletta Bio Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Cabaletta Bio stock have an average target of 33.88, with a low estimate of 25 and a high estimate of 50. The average target predicts an increase of 153.97% from the current stock price of 13.34.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cabaletta Bio stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $50 | Buy | Reiterates | $50 | +274.81% | Apr 5, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $26 → $30 | Strong Buy | Maintains | $26 → $30 | +124.89% | Apr 4, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $50 | Buy | Reiterates | $50 | +274.81% | Mar 22, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $34 → $35 | Buy | Maintains | $34 → $35 | +162.37% | Mar 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $30 | Strong Buy | Maintains | $25 → $30 | +124.89% | Mar 22, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
6.38M
EPS This Year
-1.94
from -1.65
EPS Next Year
-2.13
from -1.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 52.5M | 15.8M | 240.5M | 735.0M |
| Avg | n/a | 6.4M | 2.6M | 80.6M | 291.0M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 147.1% | 9,329.4% | 811.6% |
| Avg | - | - | -60.0% | 3,062.0% | 260.9% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.31 | -0.99 | -1.87 | 0.19 | 3.48 |
| Avg | -1.94 | -2.13 | -2.31 | -1.41 | -0.11 |
| Low | -2.24 | -2.78 | -2.99 | -2.76 | -3.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.